U.S. Intravenous Immunoglobulin Market Size, Share, Growth Analysis, By Application(Primary Immunodeficiency, Chronic Inflammatory), By Distribution Channels(Hospital Pharmacy, Specialty Pharmacy) - Industry Forecast 2023-2030

U.S. Intravenous Immunoglobulin Market size was valued at USD 5.36 billion in 2021 and is poised to grow from USD 5.78 billion in 2022 to USD 9.85 billion by 2030, at a CAGR of 7.9% during the forecast period (2023-2030).

The demand for immunoglobulin replacement therapy to address Primary Immunodeficiency Diseases (PIDD) is on the rise, serving as a primary catalyst for the growth of the U.S. Intravenous Immunoglobulin (IVIG) market. Another significant driver is the continual approval of new medications, broadening the spectrum of available treatments for patients. The surge in home infusion therapy adoption, attributed to the compromised immunity of immunocompromised patients and the secure administration of medications at home, is also noteworthy, and this trend is expected to persist post-pandemic. The COVID-19 pandemic has markedly influenced market dynamics, causing a shortage of immunoglobulin products in the U.S. IVIG market due to increased demand for plasma products in treating SARS-CoV-2 patients and a decline in plasma donations during the pandemic. The ensuing strain on the plasma supply system further exacerbated the supply issues in the early months of 2021. Businesses are exploring Immunoglobulin Intravenous (IGIV) therapies as potential treatments, and increased approval in the coming years could lead to higher treatment adoption. However, the high cost of immunoglobulin therapy in the U.S., with a typical session cost of approximately USD 9,720 and a monthly cost of USD 41,796 for 4.3 sessions, poses a barrier to widespread IVIG utilization. Patients without insurance or Medicare face challenges in accessing care, as the average annual cost of treating a Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patient surpasses USD 136,000. Key manufacturers are intensifying efforts to obtain approvals for new products, addressing the growing demand for IVIG from patients with diverse needs encompassing autoimmune, neurological, hematological, and immunodeficiency disorders treated with IVIG replacement therapy.

Top-down and bottom-up approaches were used to estimate and validate the size of the U.S. Intravenous Immunoglobulin Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

U.S. Intravenous Immunoglobulin Market Segmental Analysis

The U.S. intravenous immunoglobulin market is segmented on the basis of application, distribution channels and region. By application, the market is segmented into primary immunodeficiency, chronic inflammatory, demyelinating polyradiculoneuropathy, congenital aids, chronic lymphocytic leukemia, myasthenia gravis, multifocal motor neuropathy, immune thrombocytopenia, kawasaki disease, guillain-barre syndrome. By distribution channels, market is segmented into hospital pharmacy, specialty pharmacy, others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the U.S. Intravenous Immunoglobulin Market

In the realm of frozen desserts, manufacturers persistently pursue innovation by unveiling novel flavors, textures, and formats to align with changing consumer tastes. This encompasses the introduction of healthier alternatives like low-fat, low-sugar, and dairy-free options to address the increasing demand for more nutritious treats. Simultaneously, a burgeoning inclination towards premium and artisanal frozen desserts is observed in the U.S. market, with consumers expressing a willingness to invest in higher-quality products crafted from premium ingredients and featuring distinctive flavor combinations. This trend has spurred the emergence and expansion of small-batch producers and artisanal ice cream shops, highlighting a shift towards premiumization and a preference for handcrafted offerings.

Restraints in the U.S. Intravenous Immunoglobulin Market

The expenses associated with ingredients in frozen desserts, encompassing items like dairy products, fruits, and flavorings, are susceptible to notable fluctuations. These varying costs can exert an impact on the profit margins of manufacturers, particularly for smaller producers who may lack the purchasing influence wielded by larger corporations. Effectively navigating these cost fluctuations while upholding product quality and setting competitive pricing poses a considerable challenge.

Market Trends of the U.S. Intravenous Immunoglobulin Market

Even as the frozen dessert market witnesses an increasing focus on healthier alternatives, the desire for indulgent and decadent treats remains a robust driving force. Consumers continue to pursue rich, creamy, and luscious frozen delights, such as premium ice creams, gelatos, and opulent frozen novelties. In response to this demand, manufacturers persist in providing sumptuous flavors and textures to gratify these cravings for indulgence.